Literature DB >> 24692768

Bioequivalence of Two Formulations of a Single Oral Dose of 500-mg Azithromycin Granules: A Randomized, Open-Label, Two-Period Crossover Study in Healthy Han Chinese Volunteers.

Jing Ren1, Xue-Hua Jiang1, Kejia Li1, Chuanchuan Zhang1, Chenrui Li1, Ling Wang1.   

Abstract

BACKGROUND: In recent years, the use of generic drugs has been increasing due to their effectiveness and to the increasing variety of drugs that are now available in generic formulations. Although several generic oral formulations of azithromycin are available in China, information concerning the bioavailability of these formulations in the Chinese population is unavailable.
OBJECTIVE: The purpose of this study was to compare the bioequivalence and tolerability of a single oral dose of 2 commercial brands of 500-mg azithromycin granules in healthy Han Chinese volunteers.
METHODS: In a randomized, open-label, 2-period crossover study, the bioequivalence and tolerability of 2 commercial formulations of azithromycin granules (test: Dayin Ocean Biochemical Company Ltd., Shandong, China; reference: Taiyang Drug Company Ltd., Beijing, China) were compared in healthy adult Han Chinese volunteers. Both the test and the reference formulations were administered to each subject. The 2 treatment phases were separated by a 3-week washout period. Liquid chromatography-tandem mass spectrometry was used to determine plasma drug concentrations. The formulations were considered bioequivalent if the natural log-transformed ratios of Cmax and AUC were within the predetermined equivalence range of 70% to 143% and 80% to 125%, respectively, and if P ≤ 0.05 for the 90% CIs.
RESULTS: Twenty-four male Han Chinese volunteers (mean [SD] age, 21.0 [2.0] years [range, 18-25 years]; mean [SD] weight, 67.6 [5.6] kg [range, 56-81 kg]; mean [SD] height, 176.0 [5.0] cm [range, 165-188 cm]) were enrolled. Twenty-two subjects completed the study, with 2 withdrawing for personal reasons. No period or sequence effect was observed. The 90% CIs for the corresponding ratios of Cmax, AUC from hour 0 to time t, and AUC from hour 0 to any time point were 85.9 to 103.9, 83.6 to 106.0, and 84.7 to 105.9 (in the 2 one-sided t tests; all, P < 0.05), respectively. Similar results were found in data without a logarithmic transformation. There were no significant differences in the plasma concentration-time curves of the test and reference formulations. No adverse events were reported by the subjects or revealed by clinical or laboratory tests.
CONCLUSIONS: Single oral doses of 2 commercial brands of azithromycin granules (500 mg) were equivalent with regard to the rate and extent of absorption among these healthy Han Chinese volunteers. Both formulations were well tolerated.

Entities:  

Keywords:  Han Chinese volunteers; azithromycin; bioequivalence; mass spectrometry; pharmacokinetic parameters

Year:  2007        PMID: 24692768      PMCID: PMC3969918          DOI: 10.1016/j.curtheres.2007.10.005

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  9 in total

1.  High performance liquid chromatographic determination of azithromycin in serum using fluorescence detection and its application in human pharmacokinetic studies.

Authors:  Gholamreza Bahrami; Shahla Mirzaeei; Amir Kiani
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-06-25       Impact factor: 3.205

2.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

3.  Quantitative determination of azithromycin in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study.

Authors:  Ben-Mei Chen; Yi-Zeng Liang; Xiang Chen; Shao-Gang Liu; Fu-Liang Deng; Ping Zhou
Journal:  J Pharm Biomed Anal       Date:  2006-07-05       Impact factor: 3.935

4.  Bioavailability of two oral formulations of azithromycin 500 mg: a randomized, open-label, two-period crossover comparison in healthy Mexican adult subjects.

Authors:  Alfredo Piñeyro-López; Everardo Pineyro-Garza; Oscar Torres-Alanís; Raúl Reyes-Araiza; Magdalena Gómez Silva; Noemí Wacksman; Rubén Luján Rangel; Alberto de Lago; Mario González-de la Parra; Salvador Namur
Journal:  Clin Ther       Date:  2005-10       Impact factor: 3.393

5.  Quantitative determination of azithromycin in plasma, blood and isolated neutrophils by liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl-chloride and fluorescence detection.

Authors:  Erik Wilms; Henk Trumpie; Wim Veenendaal; Daan Touw
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-01-05       Impact factor: 3.205

6.  Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.

Authors:  Antonio Portolés; Ana Terleira; Susana Almeida; Mar García-Arenillas; Mari-Cruz Caturla; August Filipe; Emilio Vargas
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

Review 7.  Analysis of macrolide antibiotics.

Authors:  I Kanfer; M F Skinner; R B Walker
Journal:  J Chromatogr A       Date:  1998-07-03       Impact factor: 4.759

8.  Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens.

Authors:  A Ferrara; C Dos Santos; M Cimbro; G G Grassi
Journal:  Int J Antimicrob Agents       Date:  1996-08       Impact factor: 5.283

9.  In-vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells.

Authors:  P B Wyrick; C H Davis; S T Knight; J Choong
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

  9 in total
  1 in total

1.  Bioequivalence of 2 azithromycin capsule formulations: a randomized, single-dose, open-label, 2-period crossover study in healthy male pakistani volunteers.

Authors:  Zafar Iqbal; Muhammad Imran Khan; Abbas Khan; Abad Khan; Yasar Shah; Lateef Ahmad
Journal:  Curr Ther Res Clin Exp       Date:  2011-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.